Naftopidil is indicated for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS). It helps relieve urinary symptoms but does not reduce the size of the prostate gland.

Naftopidil is a selective α1-adrenergic receptor antagonist with greater affinity for the α1D subtype. It relaxes smooth muscle in the prostate gland and urethra, allowing easier urine flow. It also helps reduce detrusor muscle overactivity, improving urinary symptoms.

Naftopidil should be taken orally after meal. Swallow it as a whole without crushing or chewing it. In general, for adults, start with Naftopidil 25 once a day. If the effect is insufficient, the dosage may be gradually increased to 50 to 75 mg once a day at intervals of 1 to 2 weeks. The dosage may be adjusted according to age or symptoms. The maximum daily dose is 75 mg.

Hepatic impairment: Dosage adjustment may be required in severe hepatic impairment as this can affect the metabolism of the drug.

Renal impairment: Dosage adjustment is not required in patients with renal impairment.

Use in children and adolescents: Safety and effectiveness have not been established in patients below 18 years of age.

Concomitant use of Naftopidil with painkillers, anticoagulants (blood thinners), medicines used for rheumatoid arthritis, anti-anxiety drugs, and antifungal agents may increase the risk of side effects.

Contraindicated in patients with known hypersensitivity to Naftopidil or any component of the product.

The most common side effects include dizziness, headache, fatigue, blurred vision, and gastrointestinal discomfort.

Pregnancy: There are no well-controlled studies in pregnant women regarding risks such as birth defects, miscarriage, or adverse maternal or fetal outcomes.
Lactation: There is no sufficient data regarding its presence in breast milk or its effects on the nursing infant or milk production.

Caution should be taken in patients with electrolyte imbalance, orthostatic hypotension, or diabetes. This medicine may cause sudden blood pressure drop leading to temporary loss of consciousness.

In case of overdose, symptomatic and supportive treatment should be provided as needed.

BPH / Urinary retention / Urinary incontinence therapy

Store below 30°C in a dry place, protected from light. Keep out of reach of children.